Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey
The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and thrombolysis 2021-02, Vol.51 (2), p.466-474 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 474 |
|---|---|
| container_issue | 2 |
| container_start_page | 466 |
| container_title | Journal of thrombosis and thrombolysis |
| container_volume | 51 |
| creator | Uludağ, Ömer Bektaş, Murat Çene, Erhan Sezer, Murat Şahinkaya, Yasemin Gül, Ahmet Inanç, Murat Öcal, Lale Artim-Esen, Bahar |
| description | The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT (
n
= 58) and VT + PM (
n
= 29) groups when compared to PM (
n
= 11) group (10.6 ± 3.7 vs 7.4 ± 2.9,
P
= 0.005; 10.7 ± 4 vs 7.4 ± 2.9,
P
= 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6,
P
= 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis (
n
= 11) and APS nephropathy (
n
= 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7,
P
= 0.02; 12.4 ± 2.9 vs 10 ± 3.8,
P
= 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for developing vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy. |
| doi_str_mv | 10.1007/s11239-020-02195-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2418126602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2418126602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-53863c11ac4ff111461daa69e3eb17526e2034476952ae4c7c9617ba5030d89c3</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhoO4uOPqH_AgAS9e2q18dTrHZfFjYUFhd8VbyKSrZzL2JG3Sjcy_N-vsKnjwUBRUnvdNUS8hrxi8YwD6vDDGhWmAQy1mVCOfkBVTWjRa8m9PyQoMN40SoE7J81J2AGAM8GfkVHDVdbwzK_LzqxtD7-aQIk0DnbdIXb9byow93Yxp7Ubq4hymbSq1xjCFnpZD7HPaIy0-ZaQhUkdLiJsRqcc415FP25Tne8OLLzd0qvZ1XuhQVfR2yd_x8IKcDG4s-PKhn5G7D-9vLz81158_Xl1eXDdeaDXX5btWeMacl8PAGJMt651rDQpcM614ixyElLo1ijuUXnvTMr12CgT0nfHijLw9-k45_ViwzHYfisdxdBHTUiyXrGO8bYFX9M0_6C4tOdbtKtXVyykNqlL8SPmcSsk42CmHvcsHy8Dex2KPsdgai_0di5VV9PrBelnvsf8jecyhAuIIlPoUN5j__v0f218OHZgr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489905705</pqid></control><display><type>article</type><title>Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Uludağ, Ömer ; Bektaş, Murat ; Çene, Erhan ; Sezer, Murat ; Şahinkaya, Yasemin ; Gül, Ahmet ; Inanç, Murat ; Öcal, Lale ; Artim-Esen, Bahar</creator><creatorcontrib>Uludağ, Ömer ; Bektaş, Murat ; Çene, Erhan ; Sezer, Murat ; Şahinkaya, Yasemin ; Gül, Ahmet ; Inanç, Murat ; Öcal, Lale ; Artim-Esen, Bahar</creatorcontrib><description>The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT (
n
= 58) and VT + PM (
n
= 29) groups when compared to PM (
n
= 11) group (10.6 ± 3.7 vs 7.4 ± 2.9,
P
= 0.005; 10.7 ± 4 vs 7.4 ± 2.9,
P
= 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6,
P
= 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis (
n
= 11) and APS nephropathy (
n
= 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7,
P
= 0.02; 12.4 ± 2.9 vs 10 ± 3.8,
P
= 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for developing vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-020-02195-4</identifier><identifier>PMID: 32588289</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Antibodies, Antiphospholipid - analysis ; Antiphospholipid antibodies ; Antiphospholipid syndrome ; Antiphospholipid Syndrome - complications ; Antiphospholipid Syndrome - diagnosis ; Autoimmune diseases ; Cardiology ; Cardiovascular diseases ; Female ; Heart Disease Risk Factors ; Hematology ; Humans ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - diagnosis ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Morbidity ; Nephropathy ; Pregnancy ; Pregnancy Complications - diagnosis ; Pregnancy Complications - etiology ; Retrospective Studies ; Risk Assessment ; Risk factors ; Systemic lupus erythematosus ; Thrombosis ; Thrombosis - diagnosis ; Thrombosis - etiology ; Turkey - epidemiology</subject><ispartof>Journal of thrombosis and thrombolysis, 2021-02, Vol.51 (2), p.466-474</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-53863c11ac4ff111461daa69e3eb17526e2034476952ae4c7c9617ba5030d89c3</citedby><cites>FETCH-LOGICAL-c375t-53863c11ac4ff111461daa69e3eb17526e2034476952ae4c7c9617ba5030d89c3</cites><orcidid>0000-0001-9928-7766</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11239-020-02195-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11239-020-02195-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32588289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uludağ, Ömer</creatorcontrib><creatorcontrib>Bektaş, Murat</creatorcontrib><creatorcontrib>Çene, Erhan</creatorcontrib><creatorcontrib>Sezer, Murat</creatorcontrib><creatorcontrib>Şahinkaya, Yasemin</creatorcontrib><creatorcontrib>Gül, Ahmet</creatorcontrib><creatorcontrib>Inanç, Murat</creatorcontrib><creatorcontrib>Öcal, Lale</creatorcontrib><creatorcontrib>Artim-Esen, Bahar</creatorcontrib><title>Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT (
n
= 58) and VT + PM (
n
= 29) groups when compared to PM (
n
= 11) group (10.6 ± 3.7 vs 7.4 ± 2.9,
P
= 0.005; 10.7 ± 4 vs 7.4 ± 2.9,
P
= 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6,
P
= 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis (
n
= 11) and APS nephropathy (
n
= 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7,
P
= 0.02; 12.4 ± 2.9 vs 10 ± 3.8,
P
= 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for developing vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy.</description><subject>Adult</subject><subject>Antibodies, Antiphospholipid - analysis</subject><subject>Antiphospholipid antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Antiphospholipid Syndrome - complications</subject><subject>Antiphospholipid Syndrome - diagnosis</subject><subject>Autoimmune diseases</subject><subject>Cardiology</subject><subject>Cardiovascular diseases</subject><subject>Female</subject><subject>Heart Disease Risk Factors</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Nephropathy</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - diagnosis</subject><subject>Pregnancy Complications - etiology</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk factors</subject><subject>Systemic lupus erythematosus</subject><subject>Thrombosis</subject><subject>Thrombosis - diagnosis</subject><subject>Thrombosis - etiology</subject><subject>Turkey - epidemiology</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU2LFDEQhoO4uOPqH_AgAS9e2q18dTrHZfFjYUFhd8VbyKSrZzL2JG3Sjcy_N-vsKnjwUBRUnvdNUS8hrxi8YwD6vDDGhWmAQy1mVCOfkBVTWjRa8m9PyQoMN40SoE7J81J2AGAM8GfkVHDVdbwzK_LzqxtD7-aQIk0DnbdIXb9byow93Yxp7Ubq4hymbSq1xjCFnpZD7HPaIy0-ZaQhUkdLiJsRqcc415FP25Tne8OLLzd0qvZ1XuhQVfR2yd_x8IKcDG4s-PKhn5G7D-9vLz81158_Xl1eXDdeaDXX5btWeMacl8PAGJMt651rDQpcM614ixyElLo1ijuUXnvTMr12CgT0nfHijLw9-k45_ViwzHYfisdxdBHTUiyXrGO8bYFX9M0_6C4tOdbtKtXVyykNqlL8SPmcSsk42CmHvcsHy8Dex2KPsdgai_0di5VV9PrBelnvsf8jecyhAuIIlPoUN5j__v0f218OHZgr</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Uludağ, Ömer</creator><creator>Bektaş, Murat</creator><creator>Çene, Erhan</creator><creator>Sezer, Murat</creator><creator>Şahinkaya, Yasemin</creator><creator>Gül, Ahmet</creator><creator>Inanç, Murat</creator><creator>Öcal, Lale</creator><creator>Artim-Esen, Bahar</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9928-7766</orcidid></search><sort><creationdate>20210201</creationdate><title>Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey</title><author>Uludağ, Ömer ; Bektaş, Murat ; Çene, Erhan ; Sezer, Murat ; Şahinkaya, Yasemin ; Gül, Ahmet ; Inanç, Murat ; Öcal, Lale ; Artim-Esen, Bahar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-53863c11ac4ff111461daa69e3eb17526e2034476952ae4c7c9617ba5030d89c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antibodies, Antiphospholipid - analysis</topic><topic>Antiphospholipid antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Antiphospholipid Syndrome - complications</topic><topic>Antiphospholipid Syndrome - diagnosis</topic><topic>Autoimmune diseases</topic><topic>Cardiology</topic><topic>Cardiovascular diseases</topic><topic>Female</topic><topic>Heart Disease Risk Factors</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Nephropathy</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - diagnosis</topic><topic>Pregnancy Complications - etiology</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk factors</topic><topic>Systemic lupus erythematosus</topic><topic>Thrombosis</topic><topic>Thrombosis - diagnosis</topic><topic>Thrombosis - etiology</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uludağ, Ömer</creatorcontrib><creatorcontrib>Bektaş, Murat</creatorcontrib><creatorcontrib>Çene, Erhan</creatorcontrib><creatorcontrib>Sezer, Murat</creatorcontrib><creatorcontrib>Şahinkaya, Yasemin</creatorcontrib><creatorcontrib>Gül, Ahmet</creatorcontrib><creatorcontrib>Inanç, Murat</creatorcontrib><creatorcontrib>Öcal, Lale</creatorcontrib><creatorcontrib>Artim-Esen, Bahar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uludağ, Ömer</au><au>Bektaş, Murat</au><au>Çene, Erhan</au><au>Sezer, Murat</au><au>Şahinkaya, Yasemin</au><au>Gül, Ahmet</au><au>Inanç, Murat</au><au>Öcal, Lale</au><au>Artim-Esen, Bahar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>51</volume><issue>2</issue><spage>466</spage><epage>474</epage><pages>466-474</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). The aGAPSS was calculated for each patient as previously defined. Mean aGAPSS of the cohort was calculated as 10.2 ± 3.8. Significantly higher aGAPSS values were seen in VT (
n
= 58) and VT + PM (
n
= 29) groups when compared to PM (
n
= 11) group (10.6 ± 3.7 vs 7.4 ± 2.9,
P
= 0.005; 10.7 ± 4 vs 7.4 ± 2.9,
P
= 0.008, respectively), mainly due to lower frequencies of cardiovascular risk factors in PM. Higher aGAPPS values were also associated with recurrent thrombosis (11.6 ± 3.7 vs 9.9 ± 3.6,
P
= 0.04). Regarding extra-criteria manifestations, patients with livedo reticularis (
n
= 11) and APS nephropathy (
n
= 9) had significantly higher aGAPSS values (12.9 ± 3.4 vs 9.9 ± 3.7,
P
= 0.02; 12.4 ± 2.9 vs 10 ± 3.8,
P
= 0.04, respectively). The computed AUC demonstrated that aGAPSS values ≥10 had the best diagnostic accuracy for thrombosis. Our results suggest that patients with higher aGAPSS values are at higher risk for developing vascular thrombosis (either first event or recurrence) and extra-criteria manifestations, especially livedo reticularis and APS nephropathy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32588289</pmid><doi>10.1007/s11239-020-02195-4</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9928-7766</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-5305 |
| ispartof | Journal of thrombosis and thrombolysis, 2021-02, Vol.51 (2), p.466-474 |
| issn | 0929-5305 1573-742X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2418126602 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Antibodies, Antiphospholipid - analysis Antiphospholipid antibodies Antiphospholipid syndrome Antiphospholipid Syndrome - complications Antiphospholipid Syndrome - diagnosis Autoimmune diseases Cardiology Cardiovascular diseases Female Heart Disease Risk Factors Hematology Humans Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - diagnosis Male Medicine Medicine & Public Health Middle Aged Morbidity Nephropathy Pregnancy Pregnancy Complications - diagnosis Pregnancy Complications - etiology Retrospective Studies Risk Assessment Risk factors Systemic lupus erythematosus Thrombosis Thrombosis - diagnosis Thrombosis - etiology Turkey - epidemiology |
| title | Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A30%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20the%20adjusted%20global%20antiphospholipid%20syndrome%20score%20in%20a%20single%20centre%20cohort%20of%20APS%20patients%20from%20Turkey&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Uluda%C4%9F,%20%C3%96mer&rft.date=2021-02-01&rft.volume=51&rft.issue=2&rft.spage=466&rft.epage=474&rft.pages=466-474&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-020-02195-4&rft_dat=%3Cproquest_cross%3E2418126602%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489905705&rft_id=info:pmid/32588289&rfr_iscdi=true |